Seattle Genetics

Uro Pipeline: FDA accepts priority review application for RCC treatmentAgents for bladder cancer, prostate cancer, and stress urinary incontinence are also included in this round-up of pipeline developments.
Breakthrough lymphoma drug on the horizonFDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.